장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재)
특정 표적장기 독성 - 1회 노출
구분 1
위험
P260, P264, P270, P307+P311, P321,P405, P501
예방조치문구:
P210
열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P310
삼켰다면 즉시 의료기관(의사)의 진찰을 받으시오.
P311
의료기관(의사)의 진찰을 받으시오.
(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE C화학적 특성, 용도, 생산
개요
ADHD is a neurobehavioral disorder characterized by varying degrees of
inattention, hyperactivity, and impulsivity. ADHD is typically diagnosed in
childhood and affects 7–12% of the pediatric population in the United States with
the condition often enduring into adulthood.
While the precise mechanism of action of lisdexamfetamine
in treating ADHD is not known, amphetamines are believed to inhibit the
reuptake of the neurotransmitters dopamine and noradrenaline (norepinephrine),
thereby increasing their presynaptic availability and release into extraneuronal space. The prodrug is constructed by the condensation of D-amphetamine with the activated ester (N-hydroxysuccinimide) of bis-tert-butoxycarbonylprotected L-lysine. Lisdexamfetamine is ultimately generated by treatment with hydrochloric acid in dioxane. The most common adverse events, comparable to other amphetamine formulations, were decreased appetite, insomnia, upper abdominal pain, and irritability. Lisdexamfetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, known hypersensitivity to the sympathomimetic amines, glaucoma, a predisposition to agitated states, and a history of drug abuse. In addition, the drug should not be administered during or within 14 days of treatment with monoamine oxidase inhibitors. It has also been noted that psychostimulants may exacerbate symptoms of pre-existing psychotic disorders, so caution and close observation are recommended in this patient population.
용도
Treatment of atten tion deficit hyperactivity disorder (ADHD).
(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE 준비 용품 및 원자재
원자재
준비 용품
(2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE 공급 업체